SomnusNooze e-newsletter
News, stories and updates from the world of sleep
SomnusNooze topics: News
HF Welcomes Several New Board Members
The Board of Directors of the Hypersomnia Foundation is pleased to introduce three new board members to the Board of Directors, Scientific Advisory Board, and Medical Advisory Board. Diane Powell and to announce the appointment of two new members of the... read >
EMA Recommends Approval of Pitolisant for the Treatment of Narcolepsy
On November 20, 2015, the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Bioprojet Pharma's drug pitolisant (Wakix) be approved for the treatment of narcolepsy with or without cataplexy. In... read >
The First Multi-Site Clinical Trial for IH and Type 2 Narcolepsy in the US Is Underway
ARISE 201 is the first double-blind, placebo-controlled, crossover, multicenter study of a drug (BTD-001) for the treatment of idiopathic hypersomnia (IH) and type 2 narcolepsy (T2N) in adults. More than 20 study sites throughout the United States are... read >
BUNIHPPS – An Online Research Survey for Narcolepsy & IH Patients
https://www.hypersomniafoundation.org/research-study/bunihpps/ Dear IH Community members: A research team at Boston University has developed BUNIHPPS -- a survey research study for patients with narcolepsy and idiopathic hypersomnia. Also called the... read >
Research Opportunity
Victoria University, Melbourne Australia is commencing a study about the general health and well-being of people within three groups. One group will be those with both narcolepsy and cataplexy. Cataplexy is a sudden loss of muscle tone, often triggered... read >
The HF Welcomes Celia King to the Board of Directors
As we mentioned in our September 22, 2015, issue of SomnusNooze, several people have recently joined the Board of Directors of the Hypersomnia Foundation. Last month, we introduced you to Scot Hulshizer. Today, we would like you to meet Celia King. Ms.... read >
The Hypersomnia Foundation Welcomes New Board Members
We are pleased to announce that Scot Hulshizer, Celia King, and Diane Powell have recently been elected to the Board of Directors of the Hypersomnia Foundation. In addition to bringing unique strengths as the organization thrives and grows in both scope... read >
New Flumazenil Shortage Information Available
We have continued to monitor the flumazenil shortage situation and now have some updates for you. We are offering this to you for information purposes only. To the best of our knowledge, and until now, only one pharmacy in the United States, Pavilion... read >
Emory Team to Receive Grant to More Fully Understand and Release the Parking Brake!
The Hypersomnia Foundation congratulates Dr. David Rye and the team at Emory University on their receipt of a 4-year award for nearly $3 million in total costs from the National Institute of Neurological Disorders and Stroke to study the biologic basis of... read >
HF Report on Delays in Filling Flumazenil Prescriptions
The Hypersomnia Foundation has become aware that Pavilion Pharmacy, a provider of flumazenil cream and sublingual lozenges in the United States, has been unable to fill new or renewing prescriptions for this drug. We have contacted the company owner and... read >